Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab.

Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab. Br J Dermatol. 2020 Apr 22;: Authors: Harrer A, Lang R, Kölblinger P Abstract We read with interest the BJD online publication by Gambichler and colleagues1 about a decline of programmed death (PD)-1+ circulating T regulatory cells (Tregs) predicting clinical outcome in anti-PD-1 therapy. The study highlights the potential and importance of immune monitoring in anti-PD-1 checkpoint therapy in malignant melanoma. However, their conclusion about anti-PD-1 antibody treatment effecting a decline of PD-1+ Tregs is misleading. PMID: 32319671 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research